Quest Diagnostics Incorporated
$ 209.54
1.02%
24 Feb - close price
- Market Cap 23,309,724,000 USD
- Current Price $ 209.54
- High / Low $ 209.90 / 206.35
- Stock P/E 23.92
- Book Value 65.18
- EPS 8.76
- Next Earning Report 2026-04-28
- Dividend Per Share $3.20
- Dividend Yield 1.54 %
- Next Dividend Date 2026-04-20
- ROA 0.06 %
- ROE 0.15 %
- 52 Week High 213.20
- 52 Week Low 155.09
About
Quest Diagnostics is an American clinical laboratory. A Fortune 500 company, Quest operates in the United States, Puerto Rico, Mexico, and Brazil. Quest also maintains collaborative agreements with various hospitals and clinics across the globe.
Analyst Target Price
$217.38
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-02-10 | 2025-10-21 | 2025-07-22 | 2025-04-22 | 2025-01-30 | 2024-10-22 | 2024-07-23 | 2024-04-23 | 2024-02-01 | 2023-10-24 | 2023-07-26 | 2023-04-27 |
| Reported EPS | 2.42 | 2.6 | 2.62 | 2.21 | 2.23 | 2.3 | 2.35 | 2.04 | 2.15 | 2.22 | 2.3 | 2.04 |
| Estimated EPS | 2.36 | 2.5 | 2.57 | 2.15 | 2.18 | 2.26 | 2.34 | 1.86 | 2.11 | 2.19 | 2.27 | 1.97 |
| Surprise | 0.06 | 0.1 | 0.05 | 0.06 | 0.05 | 0.04 | 0.01 | 0.18 | 0.04 | 0.03 | 0.03 | 0.07 |
| Surprise Percentage | 2.5424% | 4% | 1.9455% | 2.7907% | 2.2936% | 1.7699% | 0.4274% | 9.6774% | 1.8957% | 1.3699% | 1.3216% | 3.5533% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-04-28 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | 2.37 |
| Currency | USD |
Previous Dividend Records
| Apr 2026 | Jan 2026 | Oct 2025 | Jan 1970 | Apr 2025 | Jan 2025 | Oct 2024 | Jul 2024 | Apr 2024 | Jan 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Payment Date | 2026-04-20 | 2026-01-28 | 2025-10-20 | None | 2025-04-21 | 2025-01-29 | 2024-10-21 | 2024-07-22 | 2024-04-22 | 2024-01-31 |
| Amount | $0.86 | $0.8 | $0.8 | $0.8 | $0.8 | $0.75 | $0.75 | $0.75 | $0.75 | $0.71 |
Next Dividend Records
| Dividend per share (year): | $3.20 |
| Dividend Yield | 1.54% |
| Next Dividend Date | 2026-04-20 |
| Ex-Dividend Date | 2026-04-06 |
Recent News: DGX
2026-02-25 15:00:15
Quest Diagnostics announced that Executive Vice President & CFO Sam Samad will speak at the Leerink 2026 Global Healthcare Conference on March 11, 2026, at 8:00 a.m. Eastern Time. He will discuss the company's strategy, performance, and market developments. A live webcast of the session will be available on Quest Diagnostics' investor relations page, with an archived version accessible for two weeks afterward.
2026-02-24 16:52:15
Illumina has launched TruPath Genome, a new whole-genome testing solution designed to provide rapid and accurate insights for rare disease research. This innovative workflow boasts significantly reduced hands-on time, high throughput, and improved accuracy in difficult-to-map genomic regions, with a competitive list price of $395 per genome. Early adopters and presented data highlight its capability in resolving complex genetic variants, marking a significant advancement in genetic diagnostics.
2026-02-24 09:50:38
Labcorp (LH) is gaining investor attention following its expanded collaboration with PathAI to roll out the FDA-cleared AISight Dx digital pathology platform. Despite recent share price momentum and a solid long-term record, Labcorp is currently trading below its average analyst price target and estimated intrinsic value. The article explores the "5% Undervalued" narrative, which suggests a fair value of $300.18, and highlights potential risks like tariffs and regulatory shifts.
2026-02-24 09:44:42
Labcorp (LH) is in focus after expanding its collaboration with PathAI to roll out the FDA-cleared AISight Dx digital pathology platform across its national network. Despite recent share price momentum, the company is trading below its average analyst price target and estimated intrinsic value of $300.18, suggesting a potential undervalued opportunity. The narrative highlights anticipated revenue and earnings growth from innovative tests but also warns of risks like tariffs and pricing pressures that could impact margins.
2026-02-23 14:14:32
Illumina has unveiled an 18-month roadmap of advancements for its NovaSeq X system, promising an increase in data output by 40% to 35 billion reads, the introduction of Q70 quality scores for enhanced accuracy, and a 30% improvement in Whole-Genome Sequencing (WGS) run times. These updates, which include new flow cells and software enhancements, aim to make DNA sequencing faster, more accurate, and more cost-effective for a wide range of applications, especially in oncology and rare disease research. The enhancements will be rolled out to the existing global fleet of 8,901 NovaSeq X systems, setting a new standard for high-throughput sequencing.
2026-02-23 12:00:14
Labcorp (NYSE: LH) has expanded its collaboration with PathAI to implement the FDA-cleared AISight Dx digital pathology platform across its national network of anatomic pathology labs and hospital collaborations. This cloud-based system aims to enable fully digital workflows, integrate AI-powered image analysis, and enhance efficiency, collaboration, and patient care. The move builds on a prior strategic investment in PathAI and is expected to support Labcorp's precision medicine initiatives.
